跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ABILIFY ASIMTUFII aripiprazole (as monohydrate) 720 mg/2.4 mL prolonged release suspension for injection pre-filled syringe - TGA Drug Approval Details
Approvals
/
TGA
/
ABILIFY ASIMTUFII aripiprazole (as monohydrate) 720 mg/2.4 mL prolonged release suspension for injection pre-filled syringe
Approved
STANDARD
ABILIFY ASIMTUFII aripiprazole (as monohydrate) 720 mg/2.4 mL prolonged release suspension for injection pre-filled syringe
Lundbeck Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
ddb1c0829c83861d
Company
Lundbeck Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
ddb1c0829c83861d
Product Name
ABILIFY ASIMTUFII aripiprazole (as monohydrate) 720 mg/2.4 mL prolonged release suspension for injection pre-filled syringe
Artg Id
410032
Artg Name
ABILIFY ASIMTUFII aripiprazole (as monohydrate) 720 mg/2.4 mL prolonged release suspension for injection pre-filled syringe
Sponsor
Lundbeck Australia Pty Ltd
Company Detail Path
/organization/lundbeck-australia-pty-ltd
Artg Date
2025-02-05
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Consumer Medicine Info
https://medical-cdn.nocode.com/drug_tga/b596c29eba00452579fdc80af003f6c4.pdf
Product Information
https://medical-cdn.nocode.com/drug_tga/a93227e3848ab3ab9758837c58bbfd47.pdf
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
ddb1c0829c83861d
Type
Standard
Back to TGA Approvals